Audentes Therapeutics, Inc. (NASDAQ:BOLD) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.88) EPS for the quarter, hitting analysts’ consensus estimates of ($0.88), Bloomberg Earnings reports.

Shares of Audentes Therapeutics (NASDAQ BOLD) opened at $25.89 on Thursday. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $33.43.

A number of equities analysts have recently commented on BOLD shares. Zacks Investment Research lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. William Blair assumed coverage on Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price on the stock. Raymond James Financial, Inc. assumed coverage on Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating on the stock. Finally, Leerink Swann reissued an “outperform” rating and set a $29.00 target price (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Audentes Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $27.17.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 25,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $27.92, for a total transaction of $698,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $21.44, for a total value of $171,520.00. Following the sale, the vice president now directly owns 8,000 shares in the company, valued at $171,520. The disclosure for this sale can be found here. Over the last three months, insiders have sold 766,500 shares of company stock worth $21,443,730. 47.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/11/16/audentes-therapeutics-inc-bold-posts-earnings-results-hits-estimates.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.